Renaissance Technologies LLC Acquires 189,414 Shares of Accuray Incorporated (NASDAQ:ARAY)

Renaissance Technologies LLC raised its stake in shares of Accuray Incorporated (NASDAQ:ARAY - Free Report) by 6.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,979,998 shares of the medical equipment provider's stock after buying an additional 189,414 shares during the quarter. Renaissance Technologies LLC owned about 2.90% of Accuray worth $5,900,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Wells Fargo & Company MN lifted its stake in Accuray by 37.7% in the 4th quarter. Wells Fargo & Company MN now owns 260,071 shares of the medical equipment provider's stock worth $515,000 after purchasing an additional 71,198 shares in the last quarter. Geode Capital Management LLC boosted its stake in Accuray by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 2,186,154 shares of the medical equipment provider's stock valued at $4,329,000 after buying an additional 6,758 shares during the last quarter. Heartland Advisors Inc. grew its holdings in Accuray by 14.1% during the 4th quarter. Heartland Advisors Inc. now owns 3,824,750 shares of the medical equipment provider's stock valued at $7,573,000 after buying an additional 472,800 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Accuray by 482.4% in the 4th quarter. JPMorgan Chase & Co. now owns 242,713 shares of the medical equipment provider's stock worth $481,000 after acquiring an additional 201,037 shares during the last quarter. Finally, Prudential Financial Inc. purchased a new stake in shares of Accuray during the 4th quarter worth approximately $43,000. Institutional investors own 64.08% of the company's stock.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Accuray from a "hold" rating to a "buy" rating in a report on Friday, April 11th.

Accuray Trading Up 1.6 %

ARAY stock traded up $0.03 during midday trading on Thursday, reaching $1.56. 56,914 shares of the company traded hands, compared to its average volume of 722,495. The firm has a market capitalization of $159.90 million, a price-to-earnings ratio of -31.10 and a beta of 1.30. The company has a debt-to-equity ratio of 3.51, a quick ratio of 0.88 and a current ratio of 1.62. The business has a 50 day moving average of $1.79 and a 200-day moving average of $1.94. Accuray Incorporated has a 52-week low of $1.40 and a 52-week high of $2.95.

Accuray (NASDAQ:ARAY - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.03. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. As a group, sell-side analysts expect that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.